Mepolizumab 100mg solution in pre-filled pen and mepolizumab 100mg solution in pre-filled syringe are indicated for severe refractory eosinophilic asthma in adults and adolescents aged 12 years and over.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||26/08/2019|
|Rapid review completed||04/11/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that mepolizumab not be considered for reimbursement under the high technology drugs arrangement at the submitted price*|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act